Ovid Therapeutics Inc. OVID 深 沪
等待开盘 04-01 09:30:00 美东时间
2.22
+0.110
+5.21%
华盛通- 最 高2.30
- 今 开2.135
- 成交量 276.91万股
- 最 低 2.13
- 昨 收 2.11
- 总市值 2.89亿
- 52周最高 2.72
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.2615
- 委 比 -49.55%
- 总股本 1.30亿
- 历史最高 15.89
- 量 比 1.21
- 振 幅 8.06%
- 历史最低 0.2425
- 每 手 1
- 风险率 0.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
美股牛股 | Swarmer上市两日狂涨1000%！全球LNG命脉被炸，美股天然气概念集体大涨
踩中“AI+无人机+军工”多重风口！Swarmer上市两日狂涨1000%！全球LNG命脉被炸，天然气概念股触控科技大涨16%，Venture涨涨超14%>>
03-19 18:49
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
Ovid Therapeutics shares climb after positive epilepsy data, new trial launch, and $60 million funding boost extending runway into 2028.
03-18 22:01
Ovid Therapeutics publishes corporate presentation on OV329 and OV4071 pipeline updates
Ovid Therapeutics publishes corporate presentation on OV329 and OV4071 pipeline updates Ovid said it received regulatory approval to initiate a Phase 1 study of OV4071, an oral potassium-chloride cotransporter 2 direct activator. The company also reported that a 7 mg dose of OV329, a GABA-aminotrans
03-18 20:44
BUZZ-U.S. STOCKS ON THE MOVE-Lululemon, Swarmer, DocuSign
BUZZ-U.S. STOCKS ON THE MOVE-Lululemon, Swarmer, DocuSign Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 18 (Reuters) - U.S. stock index futures rose on Wednesday, buoyed
03-18 19:39
Earnings Scheduled For March 18, 2026
Companies Reporting Before The Bell • SailPoint (NASDAQ:SAIL) is estimated to r...
03-18 19:11
Ovid Therapeutics advances OV329 epilepsy drug, secures $60M financing
Ovid Therapeutics (OVID) shares jumped over 40% premarket as the biopharmaceutical company reported favorable safety and tolerability results for the 7 mg dose of its OV329 epilepsy drug, while expand...
03-18 18:35
Ovid Therapeutics Q4 EPS $0.06 Beats $(0.11) Estimate, Sales $718.000K Beat $13.333K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.11) by 152.63 percent. This is a 146.15 percent increase over losses of $(0.13) per share
03-18 18:09
Ovid Therapeutics Q4 net income hits USD 9.7 million as revenue jumps more than doubled to USD 0.7 million
Ovid Therapeutics Q4 net income hits USD 9.7 million as revenue jumps more than doubled to USD 0.7 million Ovid published a press release reporting fourth-quarter and full-year 2025 financial results and pipeline updates. Cash, cash equivalents and marketable securities totaled USD 90.4 million as o
03-18 18:05
Ovid Therapeutics prices USD 60 million private placement
Ovid Therapeutics prices USD 60 million private placement Ovid announced a PIPE private placement expected to raise USD 60 million in gross proceeds. The company agreed to sell 19,154,321 common shares at USD 2.01 per share. Ovid also agreed to sell pre-funded warrants for up to 10,701,710 common sh
03-18 18:01
